MedTrace Logo

Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine

NCT02003495 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2195

Last updated 2015-09-22

No results posted yet for this study

Summary

The purpose of this observer-blind study is to evaluate the safety, reactogenicity and immunogenicity of Meninggococcal (A,C,Y and W135) Conjugate Vaccine in 2 months to 6 years-old children.

Conditions

Interventions

BIOLOGICAL

MCV-ACYW135 Vaccine Group

0.5ml, intramuscular

BIOLOGICAL

MPV-ACYW135 Vaccine Group

0.5ml, intramuscular

BIOLOGICAL

MPV-A Vaccine Group

0.5ml, intramuscular

BIOLOGICAL

MCV-AC Vaccine Group

0.5ml, intramuscular

BIOLOGICAL

Hib Vaccine Group

0.5ml, intramuscular

Sponsors & Collaborators

  • Beijing Minhai Biotechnology Co., Ltd

    lead INDUSTRY

Principal Investigators

  • shengli xia · Henan Provincial Center for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
2 Months
Max Age
6 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2014-08-31
Completion
2014-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02003495 on ClinicalTrials.gov